D76.2 Hemophagocytic syndrome, infection-associated

Name of the Condition

• Hemophagocytic syndrome, infection-associated

Summary

Hemophagocytic syndrome, infection-associated is a condition characterized by excessive immune activation and uncontrolled inflammation, often triggered by infections. It involves the overproduction of immune cells, particularly histiocytes, which can damage organs such as the liver, spleen, and bone marrow. The term "infection-associated" indicates the condition is linked to an infectious process, distinguishing it from other forms of hemophagocytic syndromes.

Causes

The condition is primarily triggered by infections, including viral (e.g., Epstein-Barr virus, cytomegalovirus), bacterial, fungal, or parasitic agents. These infections can lead to dysregulated immune responses, resulting in the overactivation of histiocytes and subsequent organ damage. In some cases, the exact pathogen may not be identified, but the clinical presentation aligns with infection-associated hemophagocytic syndrome.

Risk Factors

• Severe or prolonged infections (e.g., viral, bacterial, fungal)
• Immunocompromised states (e.g., HIV, chemotherapy, organ transplantation)
• Underlying malignancies or autoimmune disorders
• Age (more common in infants, young children, and immunocompromised adults)

Symptoms

Symptoms are often nonspecific and may include:

• Persistent fever
• Fatigue or weakness
• Enlarged liver or spleen (hepatosplenomegaly)
• Low blood cell counts (anemia, thrombocytopenia, leukopenia)
• Elevated liver enzymes
• Neurological symptoms (e.g., confusion, seizures) in severe cases

Diagnosis

Diagnosis typically involves a combination of clinical evaluation, laboratory tests (e.g., complete blood count, liver function tests, ferritin levels), and imaging studies (e.g., ultrasound or CT scans to assess organ size). A bone marrow biopsy may be performed to identify hemophagocytosis (phagocytosis of blood cells by histiocytes). Infection screening (e.g., viral or bacterial cultures) is also critical to confirm the infectious trigger.

Treatment Options

Treatment focuses on addressing the underlying infection with appropriate antimicrobial therapy (e.g., antivirals, antibiotics, antifungals) and managing inflammation. Supportive care, such as blood transfusions or organ function support, may be necessary. In severe cases, immunosuppressive agents (e.g., corticosteroids) or chemotherapy may be used to control the hyperinflammatory response.

Prognosis and Follow-Up

Prognosis depends on the severity of the infection, the patient’s overall health, and the timeliness of treatment. Early intervention improves outcomes, but the condition can be life-threatening if left untreated. Follow-up includes monitoring for resolution of symptoms, organ function recovery, and recurrence of infection or inflammation.

Complications

• Multi-organ failure (e.g., liver, kidney, or respiratory failure)
• Severe anemia or bleeding due to low platelet counts
• Neurological damage
• Recurrence of infection or hemophagocytic activity

Lifestyle & Prevention

• Prompt treatment of infections to reduce risk of triggering the syndrome
• Maintaining good hygiene and avoiding exposure to known pathogens
• Regular medical check-ups for immunocompromised individuals
• Vaccinations (e.g., against viral infections) as recommended by healthcare providers

When to Seek Professional Help

Seek immediate medical attention if you experience persistent fever, unexplained fatigue, or signs of organ dysfunction (e.g., jaundice, shortness of breath) following an infection. Early evaluation is critical to prevent severe complications.

Tips for Medical Coders

When coding for hemophagocytic syndrome, infection-associated (D76.2), ensure the documentation clearly links the condition to an infectious process. Verify that the diagnosis aligns with clinical findings (e.g., laboratory results, imaging, or biopsy) and that the infectious trigger is specified or reasonably inferred. Avoid coding if the syndrome is not infection-associated or if a more specific code (e.g., for a primary or malignancy-associated hemophagocytic syndrome) is appropriate.